ASCO 2026 preview – Celcuity gets a mutant coup
The Viktoria-1 trial of gedatolisib is a hit in PIK3CA-mutant, as well as in wild-type disease.
FDA red and green lights: April 2026
Full US approval of Gilead’s Tecartus was the only positive decision last month.
An unexpected Serena knockback for Astra
A US advisory committee votes against camizestrant, but does endorse a new use for Truqap.
Merck quietly ditches its sac-tmt copy
MK-6837 has been discontinued, the company discloses.
The month ahead: May’s upcoming events
ASCO looms, while FDA decisions are due on Enhertu and Inqovi.
New clinical projects from Kumquat and Context
The two companies have been involved in recent licensing deals.
Another fianlimab fiasco for Regeneron
The company discontinues the Lag3 project in lung cancer.
